Considerations for CPX-351 in Acute Myeloid Leukemia
2 Vues
• 07/04/23
0
0
Intégrer
administrator
Les abonnés
Expert panelists Eunice Wang, MD; Harry Erba, MD, PhD; Alexander E. Perl, MD; and Jorge E. Cortes, MD, identify important considerations when treating acute myeloid leukemia with CPX-351, such as its toxicity profile and patient stratification.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires